{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:03:43Z","timestamp":1773943423302,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009324","name":"Tommy's","doi-asserted-by":"publisher","award":["80"],"award-info":[{"award-number":["80"]}],"id":[{"id":"10.13039\/501100009324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract <\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pre-eclampsia is a complex pregnancy disorder, characterised by new or worsening hypertension associated with multi-organ dysfunction. Adverse outcomes include eclampsia, liver rupture, stroke, pulmonary oedema, and acute kidney injury in the mother, and stillbirth, foetal growth restriction, and iatrogenic preterm delivery for the foetus. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing for suspected preterm pre-eclampsia has been incorporated into national guidance. The role of repeat PlGF-based testing and its effect on maternal and perinatal adverse outcomes have yet to be evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PARROT-2 trial is a multi-centre randomised controlled trial of repeat revealed PlGF-based testing compared to repeat concealed testing, in women presenting with suspected pre-eclampsia between 22<jats:sup>+0<\/jats:sup> and 35<jats:sup>+6<\/jats:sup> weeks\u2019 gestation. The primary objective is to establish whether repeat PlGF-based testing decreases a composite of perinatal severe adverse outcomes (stillbirth, early neonatal death, or neonatal unit admission). All women prior to enrolment in the trial will have an initial revealed PlGF-based test. Repeat PlGF-based tests will be performed weekly or two-weekly, depending on the initial PlGF-based test result, with results randomised to revealed or concealed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>National guidance recommends that all women presenting with suspected preterm pre-eclampsia should have a single PlGF-based test when disease is first suspected, to help rule out pre-eclampsia. Clinical and cost-effectiveness of repeat PlGF-based testing has yet to be investigated. This trial aims to address whether repeat PlGF-based testing reduces severe maternal and perinatal adverse outcomes and whether repeat testing is cost-effective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN85912420\">ISRCTN 85912420<\/jats:ext-link>. Registered on 25 November 2019<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06652-8","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T06:03:21Z","timestamp":1662098601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2)"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-7629","authenticated-orcid":false,"given":"Alice","family":"Hurrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-544X","authenticated-orcid":false,"given":"Jenie","family":"Sparkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-5671","authenticated-orcid":false,"given":"Kate","family":"Duhig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-7933","authenticated-orcid":false,"given":"Paul T.","family":"Seed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-2096","authenticated-orcid":false,"given":"Jenny","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-553X","authenticated-orcid":false,"given":"Cheryl","family":"Battersby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-8256","authenticated-orcid":false,"given":"Marcus","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-8934","authenticated-orcid":false,"given":"Rachael M.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-3132","authenticated-orcid":false,"given":"Andrew H.","family":"Shennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6219-3379","authenticated-orcid":false,"given":"Lucy C.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9050-4242","authenticated-orcid":false,"given":"Louise","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"6652_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/uog.19039","volume":"51","author":"MY Tan","year":"2018","unstructured":"Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51:743\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"6652_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13063-018-3150-1","volume":"20","author":"LC Chappell","year":"2019","unstructured":"Chappell LC, Green M, Marlow N, Sandall J, Hunter R, Robson S, et al. Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial). Trials. 2019;20:85.","journal-title":"Trials"},{"issue":"544","key":"6652_CR3","first-page":"e541","volume":"209","author":"S Lisonkova","year":"2013","unstructured":"Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(544):e541\u2013544.e512.","journal-title":"Am J Obstet Gynecol"},{"key":"6652_CR4","first-page":"2623","volume":"125","author":"YH Gong","year":"2012","unstructured":"Gong YH, Jia J, L\u00fc DH, Dai L, Bai Y, Zhou R. Outcome and risk factors of early onset severe preeclampsia. Chin Med J. 2012;125:2623\u20137.","journal-title":"Chin Med J"},{"key":"6652_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1515\/jpm-2013-0285","volume":"42","author":"J Stubert","year":"2014","unstructured":"Stubert J, Ullmann S, Dieterich M, Diedrich D, Reimer T. Clinical differences between early- and late-onset severe preeclampsia and analysis of predictors for perinatal outcome. J Perinat Med. 2014;42:617\u201327.","journal-title":"J Perinat Med"},{"key":"6652_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.earlhumdev.2017.09.010","volume":"114","author":"L Story","year":"2017","unstructured":"Story L, Chappell LC. Preterm pre-eclampsia: what every neonatologist should know. Early Hum Dev. 2017;114:26\u201330.","journal-title":"Early Hum Dev"},{"key":"6652_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","volume":"376","author":"EA Steegers","year":"2010","unstructured":"Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631\u201344.","journal-title":"Lancet"},{"key":"6652_CR8","doi-asserted-by":"publisher","first-page":"e003497","DOI":"10.1161\/CIRCOUTCOMES.116.003497","volume":"10","author":"P Wu","year":"2017","unstructured":"Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10:e003497.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"6652_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672\u201383.","journal-title":"N Engl J Med"},{"key":"6652_CR10","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","volume":"128","author":"LC Chappell","year":"2013","unstructured":"Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128:2121\u201331.","journal-title":"Circulation"},{"key":"6652_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14767050400028816","volume":"17","author":"T Chaiworapongsa","year":"2005","unstructured":"Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17:3\u201318.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"6652_CR12","volume-title":"PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecysys immunoassay sFlt-1\/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor\/BRAHMS PlGF plus Kryptor PE ratio)","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecysys immunoassay sFlt-1\/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor\/BRAHMS PlGF plus Kryptor PE ratio) 2016 https:\/\/www.nice.org.uk\/guidance\/dg23. Accessed on 25 May 2022."},{"key":"6652_CR13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler H, Hund M, Verlohren S. The sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:1785\u20136.","journal-title":"N Engl J Med"},{"key":"6652_CR14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/1471-0528.16425","volume":"127","author":"A Hurrell","year":"2020","unstructured":"Hurrell A, Beardmore-Gray A, Duhig K, Webster L, Chappell LC, Shennan AH. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation. BJOG. 2020;127:1590\u20137.","journal-title":"BJOG"},{"key":"6652_CR15","volume-title":"PLGF-based testing to help diagnose suspected preterm pre-eclampsia","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence. PLGF-based testing to help diagnose suspected preterm pre-eclampsia 2022 https:\/\/www.nice.org.uk\/guidance\/dg49. Accessed on 29 July 2022."},{"key":"6652_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/aogs.13818","volume":"99","author":"KE Duhig","year":"2020","unstructured":"Duhig KE, Webster LM, Sharp A, Gill C, Seed PT, Shennan AH, et al. Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: a case series study. Acta Obstet Gynecol Scand. 2020;99:994\u20131002.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"6652_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/uog.19178","volume":"53","author":"H Zeisler","year":"2019","unstructured":"Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennstr\u00f6m M, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol. 2019;53:367\u201375.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"305","key":"6652_CR18","first-page":"e301","volume":"225","author":"J Binder","year":"2021","unstructured":"Binder J, Kalafat E, Palmrich P, Pateisky P, Khalil A. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension. Am J Obstet Gynecol. 2021;225(305):e301\u2013305.e314.","journal-title":"Am J Obstet Gynecol"},{"key":"6652_CR19","volume-title":"Hypertension in pregnancy: diagnosis and management","author":"National Institute for Health and Care Excellence","year":"2019","unstructured":"National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management 2019. https:\/\/www.nice.org.uk\/guidance\/ng133. Accessed on 25 May 2022."},{"key":"6652_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/archdischild-2019-317501","volume":"105","author":"JWH Webbe","year":"2020","unstructured":"Webbe JWH, Duffy JMN, Afonso E, Al-Muzaffar I, Brunton G, Greenough A, et al. Core outcomes in neonatology: development of a core outcome set for neonatal research. Arch Dis Child Fetal Neonatal Ed. 2020;105:425\u201331.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"6652_CR21","first-page":"43","volume":"2","author":"C Battersby","year":"2017","unstructured":"Battersby C, Longford N, Mandalia S, Costeloe K, Modi N, group UNCNEU-Ns. Incidence and enteral feed antecedents of severe neonatal necrotising enterocolitis across neonatal networks in England, 2012-13: a whole-population surveillance study. Lancet. Gastroenterol Hepatol. 2017;2:43\u201351.","journal-title":"Gastroenterol Hepatol"},{"key":"6652_CR22","unstructured":"National Neonatal Audit Programme: A guide to the 2022 audit measures. https:\/\/www.rcpch.ac.uk\/work-we-do\/quality-improvement-patient-safety\/national-neonatal-audit-programme. Accessed on 25 May 2022."},{"key":"6652_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(10)61351-7","volume":"377","author":"P von Dadelszen","year":"2011","unstructured":"von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, C\u00f4t\u00e9 AM, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377:219\u201327.","journal-title":"Lancet"},{"key":"6652_CR24","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","volume":"393","author":"KE Duhig","year":"2019","unstructured":"Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019;393:1807\u201318.","journal-title":"Lancet"},{"key":"6652_CR25","doi-asserted-by":"crossref","unstructured":"Efron B. Better bootstrap confidence intervals. vol 82 Journal of the American Statistical Association. J Am Stat Assoc. 1987;82:171\u201385.","DOI":"10.1080\/01621459.1987.10478410"},{"key":"6652_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0140-6736(05)17965-3","volume":"365","author":"DAMOCLES Study Group NHSHTAP","year":"2005","unstructured":"DAMOCLES Study Group NHSHTAP. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365:711\u201322.","journal-title":"Lancet"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06652-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T06:07:43Z","timestamp":1662098863000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06652-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6652"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06652-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial will be conducted according to the principles of the Declaration of Helsinki (October 2008) and all applicable regulatory requirements. The conduct of this study will be in full compliance with Good Clinical Practice. Copies of the protocol, participant information leaflet, and informed consent form have been approved by Cambridge East Research Ethics Committee (19\/EE\/0322). The chief investigators or their delegate will submit and, where necessary, obtain approval from the relevant research ethics committee (REC) for any substantial amendments. All protocol modifications will be communicated promptly to sites once approved by the sponsor and the REC. Written informed consent will be obtained by the principal investigator or another member of the study team with delegated authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS has received funds from Perkin Elmer, paid to the university, to evaluate angiogenic markers. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"722"}}